TISIDB

Summary
Symbol	TRPA1
Name	transient receptor potential cation channel, subfamily A, member 1
Aliases	ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location	8q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Multi-pass membrane protein
Domain	PF12796 Ankyrin repeats (3 copies) PF00520 Ion transport protein
Function	Receptor-activated non-selective cation channel involved in detection of pain and possibly also in cold perception and inner ear function (PubMed:25389312, PubMed:25855297). Has a central role in the pain response to endogenous inflammatory mediators and to a diverse array of volatile irritants, such as mustard oil, cinnamaldehyde, garlic and acrolein, an irritant from tears gas and vehicule exhaust fumes (PubMed:25389312, PubMed:20547126). Is also activated by menthol (in vitro)(PubMed:25389312). Acts also as a ionotropic cannabinoid receptor by being activated by delta(9)-tetrahydrocannabinol (THC), the psychoactive component of marijuana (PubMed:25389312). May be a component for the mechanosensitive transduction channel of hair cells in inner ear, thereby participating in the perception of sounds. Probably operated by a phosphatidylinositol second messenger system (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0000302 response to reactive oxygen species GO:0006816 calcium ion transport GO:0006874 cellular calcium ion homeostasis GO:0006875 cellular metal ion homeostasis GO:0006979 response to oxidative stress GO:0007204 positive regulation of cytosolic calcium ion concentration GO:0009266 response to temperature stimulus GO:0009409 response to cold GO:0009581 detection of external stimulus GO:0009582 detection of abiotic stimulus GO:0009612 response to mechanical stimulus GO:0010035 response to inorganic substance GO:0019233 sensory perception of pain GO:0032844 regulation of homeostatic process GO:0032845 negative regulation of homeostatic process GO:0033555 multicellular organismal response to stress GO:0042493 response to drug GO:0042542 response to hydrogen peroxide GO:0048265 response to pain GO:0050907 detection of chemical stimulus involved in sensory perception GO:0050951 sensory perception of temperature stimulus GO:0050954 sensory perception of mechanical stimulus GO:0050955 thermoception GO:0050966 detection of mechanical stimulus involved in sensory perception of pain GO:0050968 detection of chemical stimulus involved in sensory perception of pain GO:0050974 detection of mechanical stimulus involved in sensory perception GO:0050982 detection of mechanical stimulus GO:0051208 sequestering of calcium ion GO:0051209 release of sequestered calcium ion into cytosol GO:0051235 maintenance of location GO:0051238 sequestering of metal ion GO:0051259 protein oligomerization GO:0051260 protein homooligomerization GO:0051262 protein tetramerization GO:0051282 regulation of sequestering of calcium ion GO:0051283 negative regulation of sequestering of calcium ion GO:0051289 protein homotetramerization GO:0051480 regulation of cytosolic calcium ion concentration GO:0055074 calcium ion homeostasis GO:0060401 cytosolic calcium ion transport GO:0060402 calcium ion transport into cytosol GO:0070509 calcium ion import GO:0070588 calcium ion transmembrane transport GO:0070838 divalent metal ion transport GO:0072503 cellular divalent inorganic cation homeostasis GO:0072507 divalent inorganic cation homeostasis GO:0072511 divalent inorganic cation transport GO:0097553 calcium ion transmembrane import into cytosol GO:1902656 calcium ion import into cytosol GO:2000021 regulation of ion homeostasis
Molecular Function	GO:0005216 ion channel activity GO:0005217 intracellular ligand-gated ion channel activity GO:0005261 cation channel activity GO:0005262 calcium channel activity GO:0015085 calcium ion transmembrane transporter activity GO:0015267 channel activity GO:0015276 ligand-gated ion channel activity GO:0015278 calcium-release channel activity GO:0022803 passive transmembrane transporter activity GO:0022834 ligand-gated channel activity GO:0022836 gated channel activity GO:0022838 substrate-specific channel activity GO:0046873 metal ion transmembrane transporter activity GO:0072509 divalent inorganic cation transmembrane transporter activity GO:0097603 temperature-gated ion channel activity GO:0097604 temperature-gated cation channel activity GO:0099604 ligand-gated calcium channel activity
Cellular Component	GO:0032421 stereocilium bundle GO:0098862 cluster of actin-based cell projections

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04750 Inflammatory mediator regulation of TRP channels
Reactome	R-HSA-983712: Ion channel transport R-HSA-2672351: Stimuli-sensing channels R-HSA-3295583: TRP channels R-HSA-382551: Transmembrane transport of small molecules

Summary
Symbol	TRPA1
Name	transient receptor potential cation channel, subfamily A, member 1
Aliases	ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location	8q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between TRPA1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	TRPA1
Name	transient receptor potential cation channel, subfamily A, member 1
Aliases	ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location	8q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of TRPA1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	TRPA1
Name	transient receptor potential cation channel, subfamily A, member 1
Aliases	ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location	8q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of TRPA1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.995	0.0673
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.582	0.0724
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.584	0.435
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.049	0.933
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.821	0.649
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.922	0.669
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.265	0.696
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.193	0.842
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.958	0.359
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.814	0.107
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	3.061	0.0358
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.364	0.288

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of TRPA1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	28.6	0	28.6	0.0318
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	40	0	40	0.497
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	6.8	0.6	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	6.8	0.6	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	16.7	-16.7	0.429
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	0	9.1	0.458
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	20	0	20	0.294

Summary
Symbol	TRPA1
Name	transient receptor potential cation channel, subfamily A, member 1
Aliases	ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location	8q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TRPA1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	TRPA1
Name	transient receptor potential cation channel, subfamily A, member 1
Aliases	ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location	8q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TRPA1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TRPA1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	TRPA1
Name	transient receptor potential cation channel, subfamily A, member 1
Aliases	ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location	8q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TRPA1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	TRPA1
Name	transient receptor potential cation channel, subfamily A, member 1
Aliases	ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location	8q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of TRPA1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	TRPA1
Name	transient receptor potential cation channel, subfamily A, member 1
Aliases	ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location	8q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between TRPA1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	TRPA1
Name	transient receptor potential cation channel, subfamily A, member 1
Aliases	ANKTM1; ankyrin-like with transmembrane domains 1; FEPS; transformation-sensitive protein p120; Ankyrin-like ......
Chromosomal Location	8q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting TRPA1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting TRPA1.

ID	Name	Drug Type	Targets	#Targets
DB00825	Menthol	Small Molecule	OPRK1, TRPA1, TRPM8, TRPV3	4
DB09061	Cannabidiol	Small Molecule	CACNA1G, CACNA1H, CACNA1I, CHRNA7, CNR1, CNR2, GLRA1, GLRA1, GLRA3 ......	25

Browse TRPA1